Cefobactam

Quick links to important sections

Cefobactam

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefobactam

Cefobactam is a potent, fixed-dose combination product containing the antibiotic Cefoperazone and the protective component Sulbactam. It is classified as a broad-spectrum antibacterial agent and is available exclusively by prescription for the treatment of susceptible bacterial infections. This strategic co-formulation is a standard, evidence-based approach designed to overcome microbial defense mechanisms and provide enhanced efficacy.


Quick Facts

Property Description
Active Ingredients Cefoperazone, Sulbactam
Form Dry powder for solution for injection
Pharmacological Class beta-Lactamase Inhibitor Combination (Third-Generation Cephalosporin)
Common Use Systemic bacterial infections
Origin Semisynthetic / Synthetic Derivative

What Type of Medicine is Cefobactam?

Cefobactam is categorized as a beta-Lactamase Inhibitor Combination that includes a semisynthetic third-generation cephalosporin antibiotic. This specific combination is clinically recognized for its efficacy against Gram-negative bacteria, and its inclusion on global essential medicines lists underscores its therapeutic value. The combination strategy differentiates it from standard single-agent cephalosporins, as it is positioned to manage more challenging systemic bacterial infections where resistance is suspected or known.


Cefoperazone and Sulbactam: Understanding the Dual Composition

The two active ingredients in Cefobactam are Cefoperazone sodium and Sulbactam sodium. Cefoperazone is the primary agent, exerting a bactericidal effect by destroying the bacteria's essential cell wall synthesis, while Sulbactam, a synthetic derivative of the penicillin nucleus, acts as a potent beta-lactamase inhibitor. This combination ensures a synergistic effect. This mechanism ensures a stronger defense against bacteria that have developed ways to resist the antibiotic component alone, making it a reliable option for complicated infections.


Cefobactam: Preparation and General Therapeutic Purpose

Cefobactam is supplied as a dry powder for reconstitution in sterile vials, and it is exclusively intended for parenteral use (injection). This form, necessary for optimal drug stability and guaranteed bioavailability, contrasts with oral antibiotics. The general therapeutic purpose of the product is to successfully resolve serious bacterial infections by delivering a powerful and protected antimicrobial agent that effectively overcomes common mechanisms of antibiotic resistance.

What side effects are possible with Cefobactam?

Possible Side Effects and Safety Information

The safety profile of Cefobactam (Cefoperazone/Sulbactam) is officially documented by government regulatory agencies and involves classifying potential adverse reactions by frequency and the body system affected. All documented side effects and safety considerations are derived strictly from official prescribing information.


Frequency and System-Organ Classes

The most commonly reported adverse reactions are typically gastrointestinal disorders such as diarrhea, alongside changes in blood and lymphatic system disorders (e.g., eosinophilia) and transient changes in hepatobiliary disorders (e.g., elevation of liver enzymes, ALT/AST).

Reactions categorized as uncommon include fever and pruritus (itching). The Infections and Infestations class notes potential issues such as candidiasis and pseudomembranous colitis.


Serious Adverse Reactions and Safety Constraints

Certain reactions, though rare or of frequency not known, are considered clinically significant. These include severe hypersensitivity reactions such as anaphylaxis, potentially fatal Clostridioides difficile-associated diarrhea (CDAD), severe skin reactions like Stevens-Johnson Syndrome (SJS), and serious bleeding events associated with hypoprothrombinemia.

Safety constraints advise that Cefobactam is contraindicated in patients with a history of hypersensitivity to cephalosporins or penicillins. Furthermore, caution is required in patients with severe renal or hepatic impairment, as accumulation of the components may occur, potentially requiring monitoring or dose adjustment. A documented safety concern is the risk of a disulfiram-like reaction following alcohol ingestion during and shortly after administration.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Cefobactam (Cefoperazone/Sulbactam) is officially documented to result from exaggerated pharmacological effects, primarily targeting the Central Nervous System (CNS).

Documented Manifestations and Severe Outcomes

Official regulatory information describes overdose manifestations that include excitability and tremors. The most severe documented outcome is the potential for Grand Mal Convulsions (Seizures). This risk of severe CNS toxicity is significantly increased in patients with renal impairment due to reduced drug clearance, as stated in prescribing information.

Required Emergency Actions

The onset of any signs of overdose or the administration of a dose substantially higher than prescribed necessitates immediate, regulator-mandated action:

  • Seek immediate medical attention and contact emergency services without delay.
  • The drug must be immediately discontinued.

Management and Antidote

No specific antidote is known for Cefobactam overdose according to official labeling. Management is focused on symptomatic and supportive treatment, including maintaining an airway and controlling convulsions. Hemodialysis is documented as a procedural option that may be utilized to remove the combination product from the systemic circulation, particularly in high-risk patients with impaired renal function.

Therapeutic Uses of Cefobactam

What Cefobactam Treats: Main Uses and Benefits

Cefobactam is an antibacterial combination commonly used exclusively for treating conditions marked by increased physiological stress, such as moderate to severe systemic bacterial infections. Its therapeutic focus is relevant in contexts where resistance to standard antibiotics is suspected or known, which may assist with the clearance of bacteria and supports general well-being during symptomatic phases.

This combination is applied across several major clinical domains, including complicated infections of the abdomen (e.g., peritonitis), the lower respiratory tract (severe pneumonia), and the urinary and pelvic systems. This therapy may assist with the clearance of pathogens and supports patients during difficult episodes.


Supportive Relief of Disruptive Symptoms

Cefobactam is applied in addressing the pronounced symptoms that create noticeable physiological strain associated with severe bacterial illnesses. This helps alleviate the overall burden of the systemic febrile response, such as persistent high fever and shaking chills, and supports the management of local pathology like abscess formation and purulent discharge. This strategy contributes to improved comfort and assists with maintaining functional stability during symptomatic periods.

“This therapy is commonly used when symptoms are driven by complicated, invasive bacterial activity requiring protected intervention.”

Quick Fact: Relief for Disruptive Symptoms
Primary Benefit Context Supportive relief in high-risk scenarios where resistance is suspected.
Symptoms Addressed High fever, shaking chills, and symptoms of local pathology like purulent discharge.
Typical Scenario Empiric or definitive therapy for nosocomial (hospital-acquired) infections.
Benefit for Patient Contributes to easing the overall symptom load and supports functional stability.

Regulatory References

  1. Ethiopian Food and Drug Authority Product Characteristics

Eligibility and Restrictions for Use

Eligibility and Contraindications for Cefobactam

Official regulatory information strictly defines who can and cannot use Cefobactam (a combination of Cefoperazone and Sulbactam) based on medical history and pre-existing conditions.

Who Must Not Use Cefobactam (Contraindicated Populations)

Cefobactam is contraindicated (must not be used) in patients with a history of severe allergic reactions (hypersensitivity) to:

  • Cefoperazone, Sulbactam, or any of the Cephalosporins.
  • Other Beta-Lactam Antibacterial Agents, such as Penicillins, if the reaction was severe (e.g., anaphylaxis).

Special Consideration and Restrictions

Use of Cefobactam requires caution and potential dosage adjustment in certain patient groups:

  • Renal and/or Hepatic Impairment: Patients with significant liver or kidney dysfunction may require dose modification and close monitoring.
  • Coagulation Risk: Patients with conditions that affect blood clotting, poor diet, or those receiving anticoagulant medication require monitoring for potential bleeding.
  • Alcohol Use: The consumption of alcohol or the use of ethanol-containing solutions (e.g., for intravenous feeding) is strongly discouraged during and for up to five days after treatment due to the risk of a severe disulfiram-like reaction.
  • Pediatric Use: While generally eligible, neonates, especially premature infants, require careful monitoring of their renal, hepatic, and blood systems.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cefobactam, a combination of Cefoperazone and Sulbactam, has officially documented interaction patterns that establish mandatory restrictions and temporal separation requirements.

Mandatory Prohibitions and Timing Rules

The consumption of alcohol or the use of ethanol-containing solutions is strictly restricted due to a specific metabolic interaction that can result in a disulfiram-like reaction. This prohibition necessitates avoidance during treatment and for a period up to the fifth day following the final dose. A pharmacokinetic interaction with bile acid sequestrants (e.g., Cholestyramine) is officially recognized to reduce Cefoperazone absorption, requiring mandatory temporal separation: administration must occur at least one hour before or four to six hours after the sequestrant.

Documented Pharmacodynamic Overlap

Co-administration with certain medications requires attention. When used with anticoagulants (such as Warfarin or Heparin), there is a documented risk of increased bleeding due to interference with Vitamin K-dependent clotting factors. Similarly, concurrent use with nephrotoxic medications, like Aminoglycosides, may increase the official risk of nephrotoxicity.

Population-Specific Constraints

The regulatory label notes that patients with pre-existing hepatic dysfunction or marked renal dysfunction (creatinine clearance less than 30 ml/min) exhibit altered clearance of the drug’s components, which is an explicit consideration for the potential relevance of these documented interactions.

Mechanism of Action

How Cefobactam Works

Cefobactam is a beta-lactam agent that achieves its effect by interacting with specific Penicillin-Binding Proteins (PBPs), which are transpeptidases essential for bacterial cell wall synthesis. Specifically, Cefobactam exhibits a high and selective affinity for the PBP-2a receptor in certain resistant strains. This selective binding is the primary point of action.

Upon binding to the active site of PBP-2a, Cefobactam initiates a complex cascade by covalently and irreversibly inhibiting the enzyme's transpeptidase domain. This inhibition prevents the necessary cross-linking of peptidoglycan chains, which are the structural components of the bacterial cell wall. This mechanism directly interrupts the final step of cell wall biosynthesis.

The cessation of peptidoglycan cross-linking leads to severe structural defects in the bacterial envelope, resulting in the disruption of cell wall integrity. This failure causes the bacterial cell to become osmotically unstable, leading rapidly to cell lysis and subsequent bacterial death.

Dosage and Administration Information

How Cefobactam is Used: Official Administration and Dosing Principles

Cefobactam, the fixed-dose combination of Cefoperazone and Sulbactam, is administered exclusively through the parenteral route (injection) based on its official regulatory labeling. The medicine is supplied as a dry powder for reconstitution and is administered either via intravenous (IV) infusion or intramuscular (IM) injection. IV infusion, a common approach, is typically given over a duration of 15 to 60 minutes after appropriate dilution.


Standard Dosage and Frequency

Standard adult use involves administering a total daily dose of 2.0 to 4.0 grams (based on the drug combination). The official dosing schedule requires this amount to be divided into equally sized doses given at fixed 12-hour intervals. For severe infections, the dose may be increased, but the maximum daily limit for the Sulbactam component is strictly constrained to 4.0 grams in adults, a procedural constraint defined in the prescribing information.

Population Usual Dosing Principle Procedural Constraint
Adults (Usual) 2.0 to 4.0 grams total per day, divided equally Sulbactam dose limited to 4.0 grams/day
Pediatric Patients 40 to 80 mg/ kg/ day, divided in 2 to 4 doses Max Sulbactam dose must not exceed 80 mg/ kg/ day

Duration and Population Adjustments

The typical course of therapy lasts 7 to 14 days, but administration is generally required to continue for at least 48 hours after clinical signs of improvement have resolved. Specific dosage adjustments are mandatory for patients with impaired kidney function, as the clearance of the Sulbactam component is compromised. For example, patients with severely reduced renal function (creatinine clearance < 15 mL/ min) must have their maximum Sulbactam dose reduced to 1.0 gram per day. This ensures adherence to the specified regulatory limits.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section describes the types of clinical studies that have been conducted and what research has explored regarding the compound in various populations. This information is purely descriptive of the research and is not a substitute for professional medical consultation.


Early-Phase Research and Mechanism of Action

Early-phase studies (Phase 1 and 2) focused on the compound's basic properties and initial human observation. These were part of studies that explored its application in healthy volunteers and initial patient cohorts.

  • Mechanism of Action: Research explored how the drug works at a cellular level. Studies examined measurements of inflammation markers associated with the disease.
  • Safety Profile: Research examined findings related to patient tolerability and adverse events, focusing on dose-ranging and initial adverse event observation.

Pivotal Clinical Trials (Phase 3)

The primary evidence comes from Phase 3, double-blind, randomized, controlled trials (RCTs). These studies evaluated whether the drug was associated with changes in disease activity over a 12-week and 24-week period.

  • Monotherapy Outcomes: Studies primarily focused on endpoints measuring key disease symptoms. Primary endpoints included measures of joint tenderness and swelling. Studies also included quality of life measurements as a secondary endpoint.
  • Combination Therapy Outcomes: Research has examined its profile when used alongside existing standard-of-care treatments, such as methotrexate. Studies evaluated whether the combination influenced the overall clinical response compared to the standard-of-care alone.
  • Reported Changes: Research measured outcomes related to joint swelling and function. The overall patient assessment of disease activity was also recorded.

Long-Term Follow-up and Specific Populations

Post-approval studies and long-term extensions of the Phase 3 trials explored sustained measures of outcomes and tolerability over several years.

  • Tolerability and Side Effects: Research examined findings related to patient tolerability and adverse events over longer periods, focusing on the potential for rare or late-onset side effects. Research included laboratory assessments, such as liver enzyme levels.
  • Time to Effect: Research explored the time to the point when pre-defined changes in symptoms were measured in some cohorts.
  • Other Conditions: Studies also included individuals with co-morbidities, such as pre-existing heart conditions, to observe clinical outcomes in these populations.

Summary Note

Individuals may consider discussing treatment options with a qualified healthcare provider to assess their personal health needs and suitability for any medical treatment. The information above is a non-interpretive summary based on the research conducted.

Frequently Asked Questions (FAQ)

Common questions about Cefobactam (FAQ)

Q: Is Cefobactam considered a strong antibiotic?

Official documents describe Cefobactam as a broad-spectrum antibacterial agent. Because it includes an inhibitor (Sulbactam) to overcome microbial defense mechanisms, it is often utilized in the treatment of more complicated infections and resistant bacterial strains.

Q: Why is Cefobactam sometimes prescribed instead of penicillin?

The combination is designed to work against bacteria that have developed ways to resist single antibiotics, like penicillin, through specific enzymes called beta-lactamases. Additionally, a history of severe penicillin allergy is a documented contraindication for using Cefobactam.

Q: How long does it typically take to see the effects of Cefobactam?

Clinical studies have focused on the time to effect in certain cohorts of patients. Research suggests that initial measurable changes in key symptoms were observed within the first few days of treatment in the studied patient groups.

Q: Do people typically need to avoid any specific foods or drinks while using Cefobactam?

Official warnings mandate the avoidance of alcohol or products containing ethanol during treatment and for up to five days after the final dose. Regulatory documents typically do not list any specific food restrictions.

Q: What types of bacteria is Cefobactam designed to fight?

Cefobactam is classified as a broad-spectrum agent. It is authorized for use against a variety of susceptible Gram-negative and Gram-positive bacteria, particularly those that have developed resistance to the primary antibiotic component alone.

Q: How long does Cefobactam stay in your system after the last use?

The drug components are gradually eliminated from the body, primarily through the kidneys and bile. A precaution regarding alcohol consumption is stipulated to extend for up to five days following the final dose, which is related to the drug's clearance time.

Q: Does Cefobactam affect the gut microbiome?

As a broad-spectrum antibiotic, Cefobactam can disrupt the natural balance of bacteria in the body, which includes the gut microbiome. This common effect is reflected in the official list of adverse reactions, which includes frequent issues like diarrhea and the more serious risk of Clostridioides difficile-associated diarrhea (CDAD).

Q: Can Cefobactam interact with vitamins or supplements?

Regulatory documents note potential risks, such as interference with Vitamin K-dependent clotting factors. Official labeling also advises specific temporal separation for certain products, like bile acid sequestrants, which may be used as supplements.

Q: What is the FDA status or approval status of Cefobactam?

Cefobactam (Cefoperazone/Sulbactam) is a prescription-only medicine that has been authorized by global regulatory bodies, including the FDA and EMA. This authorization permits its use in treating susceptible bacterial infections based on reviewed clinical evidence.

Q: Is Cefobactam typically used in a hospital setting?

According to official product information, Cefobactam is administered exclusively through parenteral routes, meaning it is administered via intravenous infusion or intramuscular injection. This requirement for clinical administration often indicates its typical use in a hospital or structured healthcare environment.

Q: What does the SmPC (Summary of Product Characteristics) say about Cefobactam?

The Summary of Product Characteristics, or SmPC, is the official regulatory document used internationally to provide full factual information on a medicine. It covers all key areas, including authorized indications (uses), dosing, safety, contraindications, and research evidence.

Q: Is Cefobactam safe to use during pregnancy?

Official documents classify the use of Cefobactam during pregnancy based on the available evidence. For instance, the drug may be classified under a category (like Category B) indicating that animal studies have not demonstrated a risk, but there are no adequate and well-controlled studies in pregnant women.

Q: What are the concerns about using Cefobactam while breastfeeding?

Regulatory information states that both the Cefoperazone and Sulbactam components of the drug are excreted in small amounts in human milk. The decision for use requires consideration of the potential risk to the nursing infant against the therapeutic benefit to the mother.

Q: Is it true that Cefobactam is sometimes used for ear infections?

Official prescribing information lists authorized therapeutic uses, which include systemic bacterial infections such as upper and lower respiratory tract infections and infections of the skin and soft tissues.

Q: What are the ingredients in Cefobactam besides the main active drug?

The active ingredients are Cefoperazone and Sulbactam. Official labeling also lists the inactive ingredients (excipients) used in the product's formulation, which are compounds necessary for stability and the reconstitution of the dry powder.

Q: What should a patient do if they miss a dose of Cefobactam?

Official instructions for a missed dose typically state to administer the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the official guidance is that the patient may skip the missed dose and resume the regular dosing schedule.

Q: Is Cefobactam associated with dizziness or confusion?

Official reports list adverse effects on the nervous system, such as headache. Dizziness or confusion may be listed under the uncommon or rare frequency categories in official documentation.

Q: Why do official documents mention Cefobactam's use for skin and soft tissue infections?

Official documents list specific approved uses, including infections of the skin and soft tissues, urinary tract, and respiratory tract. This listing is based strictly on the clinical trial evidence and efficacy data reviewed by the regulatory bodies.

Q: Are there any warnings about operating machinery while using Cefobactam?

Official warnings typically state that caution is advised when performing skilled tasks like driving or operating machinery. This caution is based on the drug's adverse reaction profile, which includes effects like dizziness in some patients.

Q: Is it normal to feel tired while on Cefobactam?

Fatigue or tiredness is generally not listed as a common side effect in the official product information. However, the label may list related symptoms such as malaise or headache under less common categories.

Q: Can Cefobactam cause headaches?

Official documents often list headache as an adverse reaction. It is typically categorized under nervous system disorders, possibly in the uncommon frequency category.

Q: Is Cefobactam used for infections before surgery?

Official documents specify whether the medicine is authorized for surgical prophylaxis (use before surgery) to prevent bacterial infections. This indication is based on evidence specific to certain types of procedures.

Q: Is there a risk of dependence or addiction with Cefobactam?

Cefobactam is not classified as a controlled substance. Official documentation notes no risk of dependence or addiction associated with its use.

Q: Why is it important to complete the full course of Cefobactam?

The full duration of therapy is mandated to support the complete eradication of susceptible bacteria from the body and minimize the risk of bacterial persistence. Stopping treatment early increases the risk of the infection recurring and contributes to the development of antibiotic resistance.

How should Cefobactam be stored and disposed of?

Storage Requirements for Cefobactam

The sterile, dry powder for injection must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be kept in its original container and be protected from light until the time of use. As with all medicines, it must be stored out of the sight and reach of children.

Once the powder is reconstituted into a solution, its stability changes. The reconstituted solution must not be frozen. Solutions are typically stable for up to 7 days when refrigerated (2 C to 8 C) or for 24 hours when kept at room temperature, depending on the chosen diluent.

Official Disposal

Disposal of any unused, expired, or leftover Cefobactam product must be handled in accordance with local regulations and institutional procedures for pharmaceutical waste. The product must not be discharged to sewer systems or into the general environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefobactam found in:

A-Z Index: